Phosphodiesterases as targets for modulating T-cell responses

Handbook of Experimental Pharmacology

Volumn 204, Issue , 2011, Pages 345-363

  Bjørgo, Elisa ^a   Moltu, Kristine ^a   Taskén, Kjetil ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

cAMP; CD28; T cell function; TCR

Indexed keywords

ADENYLATE CYCLASE; BETA ARRESTIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; PHOSPHODIESTERASE VII; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SILDENAFIL; T LYMPHOCYTE RECEPTOR; TADALAFIL; VARDENAFIL; CYCLIC AMP; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; RETINA S ANTIGEN;

ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMON VARIABLE IMMUNODEFICIENCY; CYTOKINE PRODUCTION; DIMERIZATION; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME SPECIFICITY; IMMUNOMODULATION; LIPID RAFT; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PULMONARY HYPERTENSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; CELL MEMBRANE; DRUG EFFECT; HUMAN; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; REVIEW;

ANIMALS; ARRESTINS; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 7; HUMANS; MEMBRANE MICRODOMAINS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PROTO-ONCOGENE PROTEINS C-AKT; T-LYMPHOCYTES;

EID: 79960920733     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-17969-3_15     Document Type: Article

References (118)

1. Aandahl EM, Aukrust P, Skalhegg BS, Muller F, Froland SS, Hansson V, Tasken K (1998) Protein kinase A type I antagonist restores immune responses of T cells from HIV-infected patients. FASEB J 12:855-862 (Pubitemid 28294675)
2. Aandahl EM, Aukrust P, Muller F, Hansson V, Tasken K, Froland SS (1999) Additive effects of IL-2 and protein kinase A type I antagonist on function of T cells from HIV-infected patients on HAART. AIDS 13:F109-F114
3. Aandahl EM, Moretto WJ, Haslett PA, Vang T, Bryn T, Tasken K, Nixon DF (2002) Inhibition of antigen-specific T cell proliferation and cytokine production by protein kinase A type I. J Immunol 169:802-808 (Pubitemid 34753436)
4. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF (2004) Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 78:2454-2459 (Pubitemid 38228938)
5. Abrahamsen H, Baillie G, Ngai J, Vang T, Nika K, Ruppelt A, Mustelin T, Zaccolo M, Houslay MD, Tasken K (2004) TCR-and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates T cell receptor signaling. J Immunol 173:4847-4858 (Pubitemid 39387765)
6. Acuto O, Mise-Omata S, Mangino G, Michel F (2003) Molecular modifiers of T cell antigen receptor triggering threshold: the mechanism of CD28 costimulatory receptor. Immunol Rev 192:21-31 (Pubitemid 36613320)
7. Appleman LJ, van Puijenbroek AA, Shu KM, Nadler LM, Boussiotis VA (2002) CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/ PKB signaling pathway in primary human T cells. J Immunol 168:2729-2736 (Pubitemid 34211650)
8. Arp J, Kirchhof MG, Baroja ML, Nazarian SH, Chau TA, Strathdee CA, Ball EH, Madrenas J (2003) Regulation of T-cell activation by phosphodiesterase 4B2 requires its dynamic redistribution during immunological synapse formation. Mol Cell Biol 23:8042-8057 (Pubitemid 37377497)
9. Aukrust P, Aandahl EM, Skalhegg BS, Nordoy I, Hansson V, Tasken K, Froland SS, Muller F (1999) Increased activation of protein kinase A type I contributes to the T cell deficiency in common variable immunodeficiency. J Immunol 162:1178-1185 (Pubitemid 29035451)
10. Baillie GS, Sood A, McPhee I, Gall I, Perry SJ, Lefkowitz RJ, Houslay MD (2003) beta-Arrestinmediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci USA 100:940-945 (Pubitemid 36183934)
11. Baillie GS, Scott JD, Houslay MD (2005) Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract. FEBS Lett 579:3264-3270 (Pubitemid 40804673)
12. Baroja ML, Cieslinski LB, Torphy TJ, Wange RL, Madrenas J (1999) Specific CD3 epsilon association of a phosphodiesterase 4B isoform determines its selective tyrosine phosphorylation after CD3 ligation. J Immunol 162:2016-2023 (Pubitemid 29288820)
13. Bazhin AV, Kahnert S, Kimpfler S, Schadendorf D, Umansky V (2010) Distinct metabolism of cyclic adenosine monophosphate in regulatory and helper CD4+ T cells. Mol Immunol 47:678-684
14. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261-273 (Pubitemid 41032989)
15. Bergman M, Mustelin T, Oetken C, Partanen J, Flint NA, Amrein KE, Autero M, Burn P, Alitalo K (1992) The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and down regulates its catalytic activity. EMBO J 11:2919-2924
16. Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108:804-811 (Pubitemid 44154611)
17. Bjorgo E, Solheim SA, Abrahamsen H, Baillie GS, Brown KM, Berge T, Okkenhaug K, Houslay MD, Tasken K (2010) Crosstalk between PI3-Kinase and cAMP-protein kinase A signaling pathways at the level of a Protein Kinase B/{beta}-arrestin/cAMP phosphodiesterase-4 complex. Mol Cell Biol 30:1660-1672
18. Bloom TJ, Beavo JA (1996) Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc Natl Acad Sci USA 93:14188-14192 (Pubitemid 26424267)
19. Bluestone JA, Abbas AK (2003) Natural versus adaptive regulatory T cells. Nat Rev Immunol 3:253-257 (Pubitemid 37323210)
20. Bolger GB, McCahill A, Huston E, Cheung YF, McSorley T, Baillie GS, Houslay MD (2003) The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-arrestins. J Biol Chem 278:49230-49238
21. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, Heib V, Becker M, Kubach J, Schmitt S, Stoll S, Schild H, Staege MS, Stassen M, Jonuleit H, Schmitt E (2007) Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 204:1303-1310 (Pubitemid 46919868)
22. Brdicka T, Pavlistova D, Leo A, Bruyns E, Korinek V, Angelisova P, Scherer J, Shevchenko A, Hilgert I, Cerny J, Drbal K, Kuramitsu Y, Kornacker B, Horejsi V, Schraven B (2000) Phosphoprotein associated with glycosphingolipid- enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation. J Exp Med 191:1591-1604 (Pubitemid 30257355)
23. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374:685-694
24. Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511
25. Conti M, Jin SL (1999) The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 63:1-38
26. Corbin JD, Francis SH, Webb DJ (2002) Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology 60:4-11 (Pubitemid 35300142)
27. Davidson D, Bakinowski M, ThomasML, Horejsi V, Veillette A (2003) Phosphorylation-dependent regulation of T-cell activation by PAG/Cbp, a lipid raft-associated transmembrane adaptor. Mol Cell Biol 23:2017-2028 (Pubitemid 36278813)
28. de Rooij J, Zwartkruis FJ, Verheijen MH, Cool RH, Nijman SM, Wittinghofer A, Bos JL (1998) Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396:474-477 (Pubitemid 28553318)
29. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204:1257-1265 (Pubitemid 46919862)
30. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK (2007) Beta-arrestins and cell signaling. Annu Rev Physiol 69:483-510
31. Diehn M, Alizadeh AA, Rando OJ, Liu CL, Stankunas K, Botstein D, Crabtree GR, Brown PO (2002) Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc Natl Acad Sci USA 99:11796-11801 (Pubitemid 34994478)
32. Erdogan S, Houslay MD (1997) Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as downregulating a novel PDE4A splice variant. Biochem J 321(Pt 1):165-175
33. Essayan DM (2001) Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 108:671-680 (Pubitemid 33096193)
34. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF (2009) Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374:695-703
35. Feldman AM, McNamara DM (2002) Reevaluating the role of phosphodiesterase inhibitors in the treatment of cardiovascular disease. Clin Cardiol 25:256-262 (Pubitemid 34568582)
36. Francis SH, Corbin JD (2005) Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. Urol Clin North Am 32:419-429, vi (Pubitemid 41607530)
37. Gardner C, Robas N, Cawkill D, Fidock M (2000) Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun 272:186-192 (Pubitemid 30444920)
38. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, Rudensky AY (2007) Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445:771-775 (Pubitemid 46279714)
39. Giembycz MA (2005) Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2:326-333 (Pubitemid 41566944)
40. Giembycz MA, Corrigan CJ, Seybold J, Newton R, Barnes PJ (1996) Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 118:1945-1958 (Pubitemid 26292562)
41. Glavas NA, Ostenson C, Schaefer JB, Vasta V, Beavo JA (2001) T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc Natl Acad Sci USA 98:6319-6324 (Pubitemid 32488237)
42. Gretarsdottir S, Thorleifsson G, Reynisdottir ST, Manolescu A, Jonsdottir S, Jonsdottir T, Gudmundsdottir T, Bjarnadottir SM, Einarsson OB, Gudjonsdottir HM, Hawkins M, Gudmundsson G, Gudmundsdottir H, Andrason H, Gudmundsdottir AS, Sigurdardottir M, Chou TT, Nahmias J, Goss S, Sveinbjornsdottir S, Valdimarsson EM, Jakobsson F, Agnarsson U, Gudnason V, Thorgeirsson G, Fingerle J, Gurney M, Gudbjartsson D, Frigge ML, Kong A, Stefansson K, Gulcher JR (2003) The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat Genet 35:131-138 (Pubitemid 37187631)
43. Guo J, Watson A, Kempson J, Carlsen M, Barbosa J, Stebbins K, Lee D, Dodd J, Nadler SG, McKinnon M, Barrish J, Pitts WJ (2009) Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation. Bioorg Med Chem Lett 19:1935-1938
44. Hanoune J, Defer N (2001) Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 41:145-174 (Pubitemid 32385886)
45. Hansen G, Jin S, Umetsu DT, ContiM(2000) Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. Proc Natl Acad Sci USA 97:6751-6756 (Pubitemid 30412786)
46. Hetman JM, Robas N, Baxendale R, Fidock M, Phillips SC, Soderling SH, Beavo JA (2000) Cloning and characterization of two splice variants of human phosphodiesterase 11A. Proc Natl Acad Sci USA 97:12891-12895
47. Holdorf AD, Green JM, Levin SD, Denny MF, Straus DB, Link V, Changelian PS, Allen PM, Shaw AS (1999) Proline residues in CD28 and the Src homology (SH)3 domain of Lck are required for T cell costimulation. J Exp Med 190:375-384 (Pubitemid 29374835)
48. Holm AM, Aukrust P, Aandahl EM, Muller F, Tasken K, Froland SS (2003) Impaired secretion of IL-10 by T cells from patients with common variable immunodeficiency-involvement of protein kinase A type I. J Immunol 170:5772-5777 (Pubitemid 36617871)
49. Houslay MD (2009) Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 35:91-100
50. Houslay MD, Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1-18 (Pubitemid 36259414)
51. Houslay MD, Schafer P, Zhang KY (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10:1503-1519 (Pubitemid 41527193)
52. Houslay MD, Baillie GS, Maurice DH (2007) cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. Circ Res 100:950-966 (Pubitemid 46598920)
53. Jimenez JL, Punzón C, Navarro J, Muñoz-Fernandez MA, Fresno M (2001) Phosphodiesterase inhibitors prevent cytokine secretion by Tlymphocytes by inhibiting nuclear factor-kappa B and nuclear factor of activated T cells activation. J pharmacol Exp Ther 299:753-759
54. Jin SL, Conti M (2002) Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA 99:7628-7633 (Pubitemid 34568742)
55. Jin SL, Richard FJ, Kuo WP, DErcole AJ, ContiM(1999) Impaired growth and fertility of cAMPspecific phosphodiesterase PDE4D-deficient mice. Proc Natl Acad Sci USA 96:11998-12003 (Pubitemid 29502847)
56. Jin SL, Lan L, Zoudilova M, Conti M (2005) Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 175:1523-1531 (Pubitemid 41023053)
57. Johansson CC, Bryn T, Yndestad A, Eiken HG, Bjerkeli V, Froland SS, Aukrust P, Tasken K (2004) Cytokine networks are pre-activated in T cells from HIV-infected patients on HAART and are under the control of cAMP. AIDS 18:171-179 (Pubitemid 38253438)
58. Jordan MS, Singer AL, Koretzky GA (2003) Adaptors as central mediators of signal transduction in immune cells. Nat Immunol 4:110-116 (Pubitemid 36193011)
59. Kadoshima-Yamaoka K, Murakawa M, Goto M, Tanaka Y, Inoue H, Murafuji H, Hayashi Y, Nagahira K, Miura K, Nakatsuka T, Chamoto K, Fukuda Y, Nishimura T (2009) Effect of phosphodiesterase 7 inhibitor ASB16165 on development and function of cytotoxic T lymphocyte. Int Immunopharmacol 9:97-102
60. Kane LP, Weiss A (2003) The PI-3 kinase/Akt pathway and T cell activation: pleiotropic pathways downstream of PIP3. Immunol Rev 192:7-20 (Pubitemid 36613319)
61. Kaupp UB, Seifert R (2002) Cyclic nucleotide-gated ion channels. Physiol Rev 82:769-824 (Pubitemid 34743338)
62. Kawabuchi M, Satomi Y, Takao T, Shimonishi Y, Nada S, Nagai K, Tarakhovsky A, Okada M (2000) Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases. Nature 404:999-1003 (Pubitemid 30243594)
63. Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE, Graybiel AM (1998) A family of cAMP-binding proteins that directly activate Rap1. Science 282:2275-2279 (Pubitemid 29004080)
64. Ke H, Wang H (2007) Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. Curr Top Med Chem 7:391-403 (Pubitemid 46358652)
65. Kim HH, Tharayil M, Rudd CE (1998) Growth factor receptor-bound protein 2 SH2/SH3 domain binding to CD28 and its role in co-signaling. J Biol Chem 273:296-301 (Pubitemid 28042208)
66. Kvale D, Ormaasen V, Kran AM, Johansson CC, Aukrust P, Aandahl EM, Froland SS, Tasken K (2006) Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment. AIDS 20:813-820 (Pubitemid 43731562)
67. Ledbetter JA, Parsons M, Martin PJ, Hansen JA, Rabinovitch PS, June CH (1986) Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. J Immunol 137: 3299-3305 (Pubitemid 17181705)
68. Li L, Yee C, Beavo JA (1999) CD3-and CD28-dependent induction of PDE7 required for T cell activation. Science 283:848-851 (Pubitemid 129501125)
69. Luan B, Zhao J, Wu H, Duan B, Shu G, Wang X, Li D, Jia W, Kang J, Pei G (2009) Deficiency of a beta-arrestin-2 signal complex contributes to insulin resistance. Nature 457:1146-1149
70. Lynch MJ, Baillie GS, Mohamed A, Li X, Maisonneuve C, Klussmann E, van Heeke G, Houslay MD (2005) RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells. J Biol Chem 280:33178-33189 (Pubitemid 41397113)
71. Mahic M, Yaqub S, Johansson CC, Tasken K, Aandahl EM (2006) FOXP3+ CD4+ CD25+adaptive regulatory T cells express cyclooxygenase-2 and suppress effector T cells by a prostaglandin E2-dependent mechanism. J Immunol 177:246-254 (Pubitemid 43939136)
72. Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, Gray A, Zarate CA Jr, Charney DS (2003) Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 53:707-742 (Pubitemid 39658487)
73. Masciarelli S, Horner K, Liu C, Park SH, Hinckley M, Hockman S, Nedachi T, Jin C, Conti M, Manganiello V (2004) Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility. J Clin Invest 114:196-205 (Pubitemid 39071624)
74. Matulef K, Zagotta WN (2003) Cyclic nucleotide-gated ion channels. Annu Rev Cell Dev Biol 19:23-44 (Pubitemid 37487341)
75. McCahill A, McSorley T, Huston E, Hill EV, Lynch MJ, Gall I, Keryer G, Lygren B, Tasken K, van Heeke G, Houslay MD (2005) In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. Cell Signal 17:1158-1173 (Pubitemid 40933535)
76. Mehats C, Andersen CB, Filopanti M, Jin SL, Conti M (2002) Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol Metab 13:29-35 (Pubitemid 36734013)
77. Michel JJ, Scott JD (2002) AKAP mediated signal transduction. Annu Rev Pharmacol Toxicol 42:235-257 (Pubitemid 34160527)
78. Michel F, Attal-Bonnefoy G, Mangino G, Mise-Omata S, Acuto O (2001) CD28 as a molecular amplifier extending TCR ligation and signaling capabilities. Immunity 15:935-945 (Pubitemid 34075374)
79. Milburn CC, Deak M, Kelly SM, Price NC, Alessi DR, Van Aalten DM (2003) Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem J 375:531-538 (Pubitemid 37433501)
80. Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR, Malloy MP, Chubb JE, Huston E, Baillie GS, Thomson PA, Hill EV, Brandon NJ, Rain JC, Camargo LM, Whiting PJ, Houslay MD, Blackwood DH, Muir WJ, Porteous DJ (2005) DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310:1187-1191 (Pubitemid 41681745)
81. Montixi C, Langlet C, Bernard AM, Thimonier J, Dubois C, Wurbel MA, Chauvin JP, Pierres M, He HT (1998) Engagement of T cell receptor triggers its recruitment to low-density detergentinsoluble membrane domains. EMBO J 17:5334-5348 (Pubitemid 28427048)
82. Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD, Isaacs JD, Lechler RI (2001) Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 98:2736-2744
83. Oh P, Schnitzer JE (2001) Segregation of heterotrimeric G proteins in cell surface microdomains. G(q) binds caveolin to concentrate in caveolae, whereas G(i) and G(s) target lipid rafts by default. Mol Biol Cell 12:685-698 (Pubitemid 33052021)
84. Okada M, Nakagawa H (1989) A protein tyrosine kinase involved in regulation of pp 60c-src function. J Biol Chem 264:20886-20893 (Pubitemid 20017891)
85. Okkenhaug K, Rottapel R (1998) Grb2 forms an inducible protein complex with CD28 through a Src homology 3 domain-proline interaction. J Biol Chem 273:21194-21202 (Pubitemid 28385409)
86. Pages F, Ragueneau M, Rottapel R, Truneh A, Nunes J, Imbert J, Olive D (1994) Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature 369:327-329 (Pubitemid 24159544)
87. Perry SJ, Baillie GS, Kohout TA, McPhee I, Magiera MM, Ang KL, Miller WE, McLean AJ, Conti M, Houslay MD, Lefkowitz RJ (2002) Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins. Science 298:834-836 (Pubitemid 35231537)
88. Povsic TJ, Kohout TA, Lefkowitz RJ (2003) Beta-arrestin1 mediates insulin-like growth factor 1 (IGF-1) activation of phosphatidylinositol 3-kinase (PI3K) and anti-apoptosis. J Biol Chem 278:51334-51339 (Pubitemid 38020372)
89. Prasad KV, Cai YC, Raab M, Duckworth B, Cantley L, Shoelson SE, Rudd CE (1994) T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. Proc Natl Acad Sci USA 91:2834-2838 (Pubitemid 24139443)
90. Prins GS, Tang WY, Belmonte J, Ho SM (2008) Perinatal exposure to oestradiol and bisphenol A alters the prostate epigenome and increases susceptibility to carcinogenesis. Basic Clin Pharmacol Toxicol 102:134-138 (Pubitemid 351143423)
91. Raab M, Cai YC, Bunnell SC, Heyeck SD, Berg LJ, Rudd CE (1995) p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: implications for T-cell costimulation. Proc Natl Acad Sci USA 92:8891-8895
92. Rouse BT, Sarangi PP, Suvas S (2006) Regulatory T cells in virus infections. Immunol Rev 212:272-286 (Pubitemid 44116714)
93. Rudd CE (1999) Adaptors and molecular scaffolds in immune cell signaling. Cell 96:5-8 (Pubitemid 29044147)
94. Ruppelt A, Mosenden R, Gronholm M, Aandahl EM, Tobin D, Carlson CR, Abrahamsen H, Herberg FW, Carpen O, Tasken K (2007) Inhibition of T cell activation by cyclic adenosine 5′-monophosphate requires lipid raft targeting of protein kinase A type I by the A-kinase anchoring protein ezrin. J Immunol 179:5159-5168
95. Sakaguchi S (2004) Naturally arising CD4 + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531-562 (Pubitemid 38680433)
96. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T (2001) Immunologic tolerance maintained by CD25 + CD4 + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182:18-32 (Pubitemid 33070205)
97. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shimizu J, Takahashi T, Nomura T (2006) Foxp3 + CD25 + CD4 + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212:8-27 (Pubitemid 44116697)
98. Skalhegg BS, Landmark BF, Doskeland SO, Hansson V, Lea T, Jahnsen T (1992) Cyclic AMPdependent protein kinase type I mediates the inhibitory effects of 3′, 5′-cyclic adenosine monophosphate on cell replication in human T lymphocytes. J Biol Chem 267:15707-15714
99. Smith FD, Scott JD (2002) Signaling complexes: junctions on the intracellular information super highway. Curr Biol 12:R32-R40 (Pubitemid 34063347)
100. Smith SJ, Brookes-Fazakerley S, Donnelly LE, Barnes PJ, Barnette MS, Giembycz MA (2003) Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol Physiol 284:L279-L289 (Pubitemid 36164362)
101. Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS, Giembycz MA (2004) Discovery of BRL 50481 [3-(N, N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8 + T-lymphocytes. Mol Pharmacol 66:1679-1689 (Pubitemid 39564796)
102. Spina D (2003) Theophylline and PDE4 inhibitors in asthma. Curr Opin Pulm Med 9:57-64 (Pubitemid 35440972)
103. Spina D (2008) PDE4 inhibitors: current status. Br J Pharmacol 155:308-315
104. Tasken K, Aandahl EM (2004) Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 84:137-167 (Pubitemid 38049878)
105. Thompson PE, Manganiello V, Degerman E (2007) Re-discovering PDE3 inhibitors-new opportunities for a long neglected target. Curr Top Med Chem 7:421-436 (Pubitemid 46358654)
106. Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Horejsi V, Schraven B, Rolstad B, Mustelin T, Tasken K (2001) Release from tonic inhibition of T cell activation through transient displacement of C-terminal Src kinase (Csk) from lipid rafts. J Biol Chem 276: 29313-29318
107. Torgersen KM, Vang T, Abrahamsen H, Yaqub S, Tasken K (2002) Molecular mechanisms for protein kinase A-mediated modulation of immune function. Cell Signal 14:1-9 (Pubitemid 34020823)
108. Vang T, Torgersen KM, Sundvold V, Saxena M, Levy FO, Skalhegg BS, Hansson V, Mustelin T, Tasken K (2001) Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J Exp Med 193:497-507 (Pubitemid 32524480)
109. Vang T, Abrahamsen H, Myklebust S, Horejsi V, Tasken K (2003) Combined spatial and enzymatic regulation of Csk by cAMP and protein kinase a inhibits T cell receptor signaling. J Biol Chem 278:17597-17600 (Pubitemid 36799360)
110. Vlachopoulos C, Terentes-Printzios D, Ioakeimidis N, Rokkas K, Stefanadis C (2009) PDE5 inhibitors in non-urological conditions. Curr Pharm Des 15:3521-3539
111. Walsh DA, Perkins JP, Krebs EG (1968) An adenosine 3′, 5′-monophosphate-dependant protein kinase from rabbit skeletal muscle. J Biol Chem 243:3763-3765
112. Xavier R, Brennan T, Li Q, McCormack C, Seed B (1998) Membrane compartmentation is required for efficient T cell activation. Immunity 8:723-732 (Pubitemid 28294519)
113. Yamaguchi H, Hendrickson WA (1996) Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 384:484-489
114. Yamamoto S, Sugahara S, Ikeda K, Shimizu Y (2007) Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059. Eur J Pharmacol 559:219-226 (Pubitemid 46295404)
115. Yang G, McIntyre KW, Townsend RM, Shen HH, Pitts WJ, Dodd JH, Nadler SG, McKinnon M, Watson AJ (2003) Phosphodiesterase 7A-deficient mice have functional T cells. J Immunol 171:6414-6420 (Pubitemid 37532069)
116. Yaqub S, Tasken K (2008) Role for the cAMP-protein kinase A signaling pathway in suppression of antitumor immune responses by regulatory T cells. Crit Rev Oncog 14:57-77
117. Zaccolo M, Pozzan T (2002) Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science 295:1711-1715 (Pubitemid 34202906)
118. Zhang W, Sloan-Lancaster J, Kitchen J, Trible RP, Samelson LE (1998) LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell 92:83-92 (Pubitemid 28053300)